Stock Analysis
- India
- /
- Life Sciences
- /
- NSEI:SUVEN
Suven Life Sciences Second Quarter 2025 Earnings: ₹2.27 loss per share (vs ₹0.58 loss in 2Q 2024)
Suven Life Sciences (NSE:SUVEN) Second Quarter 2025 Results
Key Financial Results
- Net loss: ₹496.4m (loss widened by 292% from 2Q 2024).
- ₹2.27 loss per share (further deteriorated from ₹0.58 loss in 2Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Suven Life Sciences shares are up 5.7% from a week ago.
Risk Analysis
You should learn about the 4 warning signs we've spotted with Suven Life Sciences (including 3 which are a bit unpleasant).
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NSEI:SUVEN
Suven Life Sciences
A clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally.